Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.

Published in: Journal of endocrinological investigation (2023)

Long-acting SSAs are an effective and safe initial therapy of patients with well differentiated NET, allowing tumor growth as well as symptoms control for long-time in selected patients.

Keyphrases

neuroendocrine tumors
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
molecular docking
sleep quality
patient reported